Press Releases Novartis AG Swiss Exchange

Equities

NOVNEE

CH0038459415

Market Closed - Swiss Exchange Other stock markets 11:30:02 2024-05-17 EDT			5-day change	1st Jan Change
93.55 ^CHF	+0.73%		+1.27%	+10.62%

05-16	Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	DP
05-16	Novartis: presents results of tender offer for MorphoSysy	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	05-16	GL
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	05-15	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	05-13	AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	05-10	AQ
Novartis : enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline	05-02	PU
Novartis : Q1 2024 impact and sustainability update	04-30	PU
European Commission authorises one of first ustekinumab biosimilars in Europe	04-26	AQ
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	04-24	GL
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	04-23	AQ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	04-23	GL
Novartis: Q1 Earnings Snapshot	04-23	AQ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	04-23	GL
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	04-17	GL
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	04-15	GL
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	04-12	AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis	04-12	AQ
Novartis tender offer for MorphoSys AG commences	04-11	GL
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2	04-10	AQ
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting	04-06	GL
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis under HSR Act	03-25	AQ